# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 10 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sbd9498fe08
CUTOFF DATE (today): 2025-02-07
Regulator: RBI (IN)
Matter: RBI draft: transparency in aggregation of loan products by digital lending service providers
Decisive action for this matter = the central bank issues FINAL directions/circular adopting the draft at least in substantial part.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2024-04-26 | official-forward (B) | draft_circular | "RBI invites comments on the Draft Circular on “Digital Lending – Transparency in Aggregation of Loan Products from Multiple Lenders”" | www.rbi.org.in
   Claims: In pursuance of the Statement on Developmental and Regulatory Policies dated December 8, 2023, RBI placed a draft circular on Digital Lending - Transparency in Aggregation of Loan Products from Multiple Lenders. / Addresses issuance of a regulatory framework for aggregation of loan products by Lending Service Providers (LSPs). / Comments invited by May 31, 2024.
   Excerpt: In pursuance of the announcement made in the Statement on Developmental and Regulatory Policies dated December 08, 2023 regarding issuance of a regulatory framework for aggregation of loan products by lending service providers (LSPs), the Reserve Bank of India has today placed on its website the Draft Circular on 'Digital Lending – Transparency in Aggregation of Loan Products from Multiple Lenders'. Comments/feedback, if any, may be sent by e-mail with the subject line "Comments on Draft Circular on Digital Lending – Transparency in Aggregation of Loan Products from Multiple Lenders", by May 31, 2024.
---
## SNAPSHOT S36692a77bf
CUTOFF DATE (today): 2022-09-21
Regulator: SEBI (IN)
Matter: SEBI consultation: expanding the green debt securities framework to blue/coloured bonds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (2 item(s), chronological):
[E1] 2022-08-04 | official-forward (B) | consultation_paper | "Consultation Paper on Green and Blue Bonds as a mode of Sustainable Finance" | www.sebi.gov.in
   Claims: SEBI proposed to amplify the definition of 'green debt securities', including possibly adding 'alternative' instruments such as green revenue bonds, green project bonds and green securitized bonds as defined by ICMA. / SEBI proposed introducing the concept of 'blue bonds' for ocean/marine and water-management projects, and asked whether introducing 'coloured bonds' more broadly (blue bonds for the blue economy, yellow bonds for solar power) would help increase funding channels for green projects. / SEBI sought views on reducing compliance costs for issuers of green debt securities while guarding against 'greenwashing'. / It proposed updating the list of 'eligible' green-bond sectors in line with updated ICMA Green Bond Principles.
   Excerpt: 3.2. In this context, SEBI, through this consultation paper, is seeking public comments on a proposed regulatory framework: a. to amplify the definition of green debt securities, b. to introduce the concept of blue bonds, c. to reduce the compliance cost for issuers of green debt securities with while not creating any perverse incentives that may lead to 'greenwashing'. ... 9.8 Views/comments sought on: a. Whether the above mentioned initiatives offer any scope for financing through blue bonds? b. Whether introducing coloured bonds (blue bonds for blue economy, yellow bonds for solar power) will help increase channels for funding to green projects?
[E2] 2022-08-26 | official-forward (B) | comment_period_extension | "Extension of timeline for submission of public comments on the Consultation Paper on Green and Blue Bonds as a mode of Sustainable Finance" | www.sebi.gov.in
   Claims: SEBI extended the public comment deadline for its August 4, 2022 green and blue bonds consultation from August 31 to September 30, 2022.
   Excerpt: Extension of timeline for submission of public comments on the Consultation Paper on Green and Blue Bonds as a mode of Sustainable Finance (SEBI listing entry, Aug 26, 2022).
---
## SNAPSHOT Sc5fd7bb501
CUTOFF DATE (today): 2023-07-19
Regulator: RBI (IN)
Matter: RBI draft: fair lending practice on penal charges in loan accounts
Decisive action for this matter = the central bank issues FINAL directions/circular adopting the draft at least in substantial part.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-04-12 | official-forward (B) | draft_circular | "RBI releases Draft Circular on Fair Lending Practice - Penal Charges in Loan Accounts" | www.rbi.org.in
   Claims: RBI released the Draft Circular on Fair Lending Practice - Penal Charges in Loan Accounts on April 12, 2023, following its February 8, 2023 policy statement. / Comments on that draft were invited by May 15, 2023.
   Excerpt: RBI releases Draft Circular on Fair Lending Practice - Penal Charges in Loan Accounts. In pursuance of the announcement made in the Statement on Developmental and Regulatory Policies dated February 08, 2023 regarding the review of extant regulatory guidelines on levy of penal interest, the Reserve Bank of India has released today the Draft Circular on Fair Lending Practice - Penal Charges in Loan Accounts. Comments by stakeholders on the Draft Circular may be submitted by May 15, 2023. Press Release: 2023-2024/56.
---
## SNAPSHOT S5c6eaece3e
CUTOFF DATE (today): 2025-05-10
Regulator: FDA (US)
Matter: FDA draft guidance: Benefit-Risk Considerations for Product Quality Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-05-09 | official-forward (B) | draft_guidance_availability_notice | "Benefit-Risk Considerations for Product Quality Assessments; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessm
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC) information submitted for FDA assessment as part of original new drug applications (NDAs), original biologics license applications (BLAs), or supplements to such applications, in addition to other information (e.g., inspectional findings) available to FDA during its assessment. This guidance discusses how FDA assesses risks, sources of uncertainty, and possible mitigation strategies for a product quality-related issue and how those considerations inform FDA's understanding of the potential effect on a product. This guidance also discusses how unresolved product quality issues may be addressed in the context of regulatory decision making. The guidance notes that product quality assessments are also done for abbreviated new drug applications (ANDAs), and it discusses how, in certain rare circumstances, unresolved product quality issues m
---
## SNAPSHOT S76e998842a
CUTOFF DATE (today): 2024-02-05
Regulator: RBI (IN)
Matter: RBI draft: arrangements with card networks for debit, credit and prepaid cards
Decisive action for this matter = the central bank issues FINAL directions/circular adopting the draft at least in substantial part.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-07-05 | official-forward (B) | draft_circular | "RBI invites comments on draft circular on Arrangements with Card Networks for issue of Debit, Credit and Prepaid Cards" | www.rbi.org.in
   Claims: Draft circular on Arrangements with Card Networks for issue of Debit, Credit and Prepaid Cards placed on RBI's website for stakeholder feedback. / Would mandate card issuers to offer cards on more than one card network and let customers choose among networks. / Would restrain card issuers from agreements limiting their ability to tie up with other card networks. / Comments invited by August 4, 2023.
   Excerpt: The Reserve Bank of India has today placed on its website the draft circular on Arrangements with Card Networks for issue of Debit, Credit and Prepaid Cards for feedback from stakeholders. Comments / Feedback, if any, may be sent by email, or by post to the Chief General Manager-in-Charge, Department of Payment and Settlement Systems, Central Office, Reserve Bank of India, on or before August 4, 2023. 2. The draft circular mandates card issuers (banks / non-banks) to issue cards on more than one card-network along with providing customers the facility to choose any one among the multiple card networks. It also restrains card issuers from entering into agreements that limit their ability to tie-up with other card-networks.
---
## SNAPSHOT Sa81f4594b9
CUTOFF DATE (today): 2021-04-14
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-04-21 | official-forward (B) | draft_guidance_availability_notice | "Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug Application; Draft Guidance for Industry an" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that are intended to treat emergent, life- threatening conditions, it is essential to ensure that the emergency- use injector will reliably deliver the drug or biological product as intended. This is particularly critical for drugs when failure of the injector may prevent adequate delivery of a life-saving drug to a patient. The draft guidance describes the technical considerations for demonstrating reliability of emergency-use injectors under a biologics license application (BLA), new drug application (NDA), or abbreviated new drug application (ANDA).
---
## SNAPSHOT Sdcd5aa1129
CUTOFF DATE (today): 2026-08-25
Regulator: FDA (US)
Matter: FDA draft guidance: M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (3 item(s), chronological):
[E1] 2024-10-30 | official-forward (B) | related_prior_final_guidance_notice | "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms; International Council for Harmonisation; Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms" and the supplemental document entitled "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Que
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms" and the supplemental document entitled "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Questions and Answers." The guidance describes the scientific and technical aspects of study design and data analysis to support bioequivalence (BE) assessment of orally administered immediate-release solid oral dosage forms.
[E2] 2025-05-30 | official-forward (B) | draft_guidance_availability_notice | "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver." The draft guidance was prepared under the auspices of the International Counc
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second in the ICH M13 series of guidances and describes the scientific and technical aspects of study design and data analysis to support bioequivalence (BE) assessment for additional strengths of orally administered immediate-release (IR) solid oral dosage forms (i.e., tablets, capsules, and granules/powders for oral suspension), including considerations for biowaivers. The intent of this draft guidance is to provide harmonized criteria and data that support waivers for drug applications with multiple strengths when in vivo BE has been demonstrated for at least one strength using the principles outlined in the final guidance "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms" published in October 2024.
[E3] 2025-09-08 | official-forward (B) | comment_period_reopening_notice | "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the draft guidance announced in the notice entitled "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for
   Excerpt: The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the draft guidance announced in the notice entitled "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry," published in the Federal Register of June 2, 2025. The Agency is taking this action to allow interested persons additional time to submit comments.
---
## SNAPSHOT Sc4bed2c92d
CUTOFF DATE (today): 2020-12-02
Regulator: FDA (US)
Matter: FDA draft guidance: Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated With Internal or External Hemorrhoids
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-12-06 | official-forward (B) | draft_guidance_availability_notice | "Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated With Internal or External Hemorrhoids; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Development of Locally Applied Corticosteroid Products for the Short- Term Treatment of Symptoms Associated with Internal or External Hemorrhoids." This draft guidance will serv
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Development of Locally Applied Corticosteroid Products for the Short- Term Treatment of Symptoms Associated with Internal or External Hemorrhoids." This draft guidance will serve as a focus for continued discussions among the Division of Gastroenterology and Inborn Error Products, pharmaceutical sponsors, the academic community, and the public.
---
## SNAPSHOT S4a4c8d2b21
CUTOFF DATE (today): 2022-11-28
Regulator: FDA (US)
Matter: FDA draft guidance: Mitigation Strategies To Protect Food Against Intentional Adulteration
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-02-13 | official-forward (B) | draft_guidance_availability_notice | "Mitigation Strategies To Protect Food Against Intentional Adulteration; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA, we, or Agency) is announcing the availability of a supplemental draft guidance for industry entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration: Guidance for Industry." This supplemental draft guidance document, when finalized, will
   Excerpt: The Food and Drug Administration (FDA, we, or Agency) is announcing the availability of a supplemental draft guidance for industry entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration: Guidance for Industry." This supplemental draft guidance document, when finalized, will help food facilities that manufacture, process, pack, or hold food, and that are required to register under the Federal Food, Drug, and Cosmetic Act (FD&C Act) comply with the requirements of our regulation entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration."
---
## SNAPSHOT Sb65cb93305
CUTOFF DATE (today): 2023-03-30
Regulator: SEBI (IN)
Matter: SEBI consultation: perpetual minimum unit holding requirement for REIT/InvIT sponsors
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-02-23 | official-forward (B) | consultation_paper | "Consultation Paper on Holding of Sponsor in REITs and InvITs" | www.sebi.gov.in
   Claims: SEBI proposed that the Sponsor of a REIT/InvIT be required to mandatorily hold a minimum percentage of total unit capital at all points in time on a declining schedule: 15% up to 3 years, 5% for years 3-5, 3% for years 5-10, 2% for years 10-20, and 1% after 20 years. / The mandatorily-held sponsor units would be required to be unencumbered. / SEBI proposed reviewing the norms for sponsor declassification, including permitting declassification after three years of listing subject to specified conditions. / The stated rationale was that sponsors continue to control the Investment Manager/Manager (and hence key REIT/InvIT decisions, including debt financing) well beyond the existing 3-year mandatory holding period, so interests should stay aligned for longer.
   Excerpt: 32. For alignment of interest between the Sponsor and unitholder, the following is proposed: 32.1. The Sponsor shall be required to mandatorily hold certain percentage of total unit capital, in the manner as proposed below, at all points in time: [Table 8] Upto 3 years: 15% of total unit capital; 3-5 years: 5%; 5-10 years: 3%; 10-20 years: 2%; Post 20 years: 1%. 32.2. The units required to be mandatorily held by the Sponsor(s) or Sponsor group(s) cannot be encumbered. 32.3. Further, it is proposed to review the norms for declassification...